| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Country's Decision or any other Communication
Record information and status
Record ID
115499
Status
Published
Date of creation
2020-04-14 07:20 UTC (exploitasia@gedepangrango.org)
Date of publication
2020-04-14 07:21 UTC (exploitasia@gedepangrango.org)

General information
Country submitting the decision or communication
  • Indonesia
Competent National Authority(ies) responsible for the decision or communication
Ministry of Environment
Jl. DI Panjaitan
Kebun Nanas Kav. 24 Gedung B. Lt.4
Jakarta Timur
Indonesia, 13410
Phone:+62 21 851-7163
Fax:+62 21 8590-5770
Email:kehati@menlh.go.id
Url:www.menlh.go.id
Title / Reference number of the decision or communication
KEMENTAN RI No. I. 19106070 VKC PRG
Date of the decision
2019-10-29
Is the decision taken prior to entry into force of the Protocol?
No
Jurisdiction
  • Indonesia
Is this an amendment to a previous decision / communication?
No
Decision or communication details
Subject(s) of the decision
Was the decision triggered by a request for a transboundary movement of LMOs into the country?
Yes
Exporter’s contact details
DVM, Ph.D. Robin Dalgleish (Griff)
Executive Director Regulatory Affairs, Asia Pacific
Intervet International BV
Wim de KÖrverstraat 35
P.O. BOX 31
5830 AA Boxmeer - The Netherlands
Boxmeer
Netherlands
Phone:+31 485 58 7600
Email:grabiolicensing@merck.com
Importer’s or Applicant’s contact details
DVM Khalida Noor
Associate Director Regulatory Affairs, ID-MY-SG
Associate Directore Regulatory Affairs
PT. Intervet Indonesia
Wisma BNI 46 27th Floor
Jl. jenderal sudirman Kav. 1
Jakarta Pusat 10220, Indonesia
jakarta
Indonesia
Phone:+622157897000
Email:khalida.noor@merck.com
Result of the decision
  • Approval of the import/use of the LMO(s) without conditions
Does the decision involve field trials?
No
Does the decision involve commercial release?
Yes
LMO identification
INNOVAX® ND Vaccine
Dr Leonardo Bruno Ribeiro Costa Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Risk assessment
Summary of GMO product environmental risk assessment Nobilis® rHVT-ND (Innovax®-ND)
INNOVAX® ND Vaccine
Dr Leonardo Bruno Ribeiro Costa

Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Decision document